Abstract
The mammalian target of rapamycin (mTOR) is a critical sensor of nutritional sufficiency. Although much is known about the regulation of mTOR in response to growth factors, much less is known about the regulation of mTOR in response to nutrients. Amino acids have no impact on the signals that regulate Rheb, a GTPase required for the activation of mTOR complex 1 (mTORC1). Phospholipase D (PLD) generates a metabolite, phosphatidic acid, that facilitates association between mTOR and the mTORC1 co-factor Raptor. We report here that elevated PLD activity in human cancer cells is dependent on both amino acids and glucose and that amino acid- and glucose-induced increases in mTORC1 activity are dependent on PLD. Amino acid- and glucose-induced PLD and mTORC1 activity were also dependent on the GTPases RalA and ARF6 and the type III phosphatidylinositol-3-kinase hVps34. Thus, a key stimulatory event for mTORC1 activation in response to nutrients is the generation of phosphatidic acid by PLD.
Keywords: Amino Acid, Glucose, mTOR, Phosphatidic Acid, Phospholipase D, Arf6, Nutrient Sensing, RalA, Rheb, hVps34
Introduction
The mammalian target of rapamycin (mTOR)2 is a critical regulator of cell growth and cell cycle progression. mTOR is activated in response to both growth factors and nutrients (1). mTOR exists as two complexes, mTORC1 and mTORC2. Although both mTORC1 and mTORC2 are responsive to growth factors, mTORC1 is believed to be the primary sensor of nutrient and energy sufficiency (2–4). mTORC1 is activated in response to insulin and other peptide hormones that activate type I phosphatidylinositol (PI) 3-kinases (PI3Ks) that generate PI 3,4,5-trisphosphate. The activation of mTORC1 via PI3K involves the Akt-mediated suppression of the tuberous sclerosis complex (TSC), which consists of TSC1 and TSC2. TSC1/2 functions as a GTPase-activating protein for Rheb (Ras homologue enriched in brain), a GTPase that directly interacts with and contributes to the activation of mTORC1 (2). Although Rheb is required for the amino acid stimulation of mTORC1, starving cells of amino acids has no effect on GTP loading (4–7). In addition, amino acid starvation was still able to suppress mTORC1 in cells lacking the Rheb GTPase-activating complex protein TSC2 (4–7). Therefore, although there is a requirement for GTP-bound Rheb for induction of mTORC1 by amino acids, amino acids do not impact on Rheb activity, indicating that regulation of Rheb does not stimulate mTORC1 in response to amino acids.
It was recently reported that Rag GTPases are critical for targeting mTORC1 to lysosomal compartments in response to amino acids (8–10), and a model was proposed whereby the targeting of mTOR to lysosomal membranes containing GTP-bound Rheb was sufficient to activate mTORC1 (10, 11). However, several other factors implicated in the regulation of mTORC1 in response to amino acids were not accounted for in this model. The Ras family GTPase RalA was reported to be required for amino acid induction of mTORC1 (12). Significantly, RalA is constitutively associated with phospholipase D1 (PLD1) (13, 14). PLD1 generates the lipid second messenger phosphatidic acid (PA), which is required for the activity of both mTORC1 and mTORC2 (15–17). Although RalA does not activate PLD1 directly, it stimulates the association of PLD1 with ADP-ribosylation factor (ARF) family GTPases, which do increase the activity of PLD1 (18). Significantly, ARF6 has been implicated in the response of mTORC1 to glucose (19). An important recent study also linked Rheb and PLD1. Chen and colleagues (20) reported that Rheb, like ARF and Rho family GTPases, interacts with and activates PLD1. This study suggested the possibility that the activation of Rheb in response to growth factors can induce PLD activity and the generation of the PA critical for mTORC1 activation.
Tamanoi and colleagues (21) recently identified two mTOR mutants from human cancers with point mutations that made mTOR constitutively active in the absence of nutrients. Significantly, one of these nutrient-insensitive mTOR mutants was resistant to inhibition by 1-BtOH while retaining sensitivity to rapamycin. 1-Butanol (1-BtOH) suppresses the production of PA by PLD and is used to implicate PLD activity (17). This finding indicated that a nutrient-insensitive mTOR mutant has lost its PA requirement. The insensitivity of this mutant to both nutrients and PA is consistent with the hypothesis that nutritional input into mTORC1 is mediated by PLD.
Another link between amino acids and mTOR is the class III PI3K, hVps34 (22–25). hVps34 generates PI 3-phosphate (PI-3-P) instead of the PI 3,4,5-trisphosphate generated by type I PI3Ks (26). It is not known how hVps34 contributes to the activation of mTORC1, but PI-3-P serves to recruit proteins with PX domains (26). In this regard, it is of interest that both PLD1 and PLD2 have PX domains (27, 28) that could be influenced by hVps34 activity. Thus, a common denominator for several factors previously implicated in the regulation of nutrient-dependent mTORC1 activity is PLD.
In addition to being a central regulator of the cell response to nutrients and energy, mTOR has emerged as a central player in cancer (29). mTOR signaling is dysregulated in what may be virtually all human cancers and has been widely implicated in cancer cell survival signals (29, 30). There are many mutations in the signals that mediate growth factor signaling to mTOR, such as PI3K, Akt, and the TSC (31). However, these growth factor-signaling intermediates that lead to elevated mTORC1 activity are not affected by nutrients (4). PLD, like mTORC1, has also been implicated in cancer cell survival signals (32). We report here that elevated PLD activity in human cancer cells is dependent on the presence of nutrients that stimulate mTORC1. The study suggests that PLD-generated PA represents a critical signal for nutrient sensing by mTORC1.
EXPERIMENTAL PROCEDURES
Cells, Cell Culture Conditions, and Transfection
The MDA-MB-231, T24, and Calu-1 cells used in this study were obtained from the American Type Culture Collection. All cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum.
Materials
Reagents were obtained from the following sources. Antibodies against ARF1, ARF6, Rheb, and hVps15 were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); antibodies against S6 kinase, phosphorylated S6 kinase (Thr389), hVps34, RalA, and actin were obtained from Cell Signaling. siRNAs targeting RalA (M-009235-00-0005), Rheb (M-009692-02-0005), ARF1 (M-011580-01-0005), ARF6 (M-004008-01-0005), hVps34 (M-005250-00-0005), and hVps15 (M-005025-02-0005) were obtained from Dharmacon. Insulin, 1-BtOH, and t-BtOH were from Sigma; wortmannin was from Calbiochem. DMEM (D5796) and DMEM lacking Arg, Leu, and Lys (D9443) were obtained from Sigma. 50× minimum essential medium amino acid solution without l-Gln (Sigma M5550) was used for stimulation by amino acids. For stimulation, the amino acid solution was added to a 2× concentration. Glucose-free DMEM was from Invitrogen (11966-025). PLD inhibitors for PLD1 (Compound 14, VU0379595) ((1R,2R)-N-([S]-1-{4-[5-bromo-2-oxo-2,3-dihydro-1H-benzo(d)imidazol-1-yl]piperidin-1-yl}propan-2-yl)-2-phenylcyclopropanecarboxamide) and PLD2 (Compound 22a, VU0364739) (N-(2-(1-(3-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)-2-naphthamide) were provided by Dr. H. Alex Brown (Vanderbilt University) and have been described elsewhere (33, 34).
siRNA
Cells were plated on 6-well plates at 30% confluence in medium containing 10% serum. After 1 day, cells were transfected with siRNA at 80 nm concentration using Lipofectamine RNAiMAX (Invitrogen) according to manufacturer's instructions. After 24 h, the medium was changed to fresh medium containing 10% serum, and 2 days later, cells were lysed and analyzed by Western blot.
Western Blot Analysis
Extraction of proteins from cultured cells and Western blot analysis of extracted proteins was performed using the ECL system (Thermo Scientific) as described previously (17). Relative levels of p70S6K phosphorylation were determined by measuring the intensity of the appropriate band in the autoradiograph with ImageJ software.
PLD Activity
PLD activity was determined by the transphosphatidylation reaction in the presence of 0.8% 1-BtOH as described previously (17). Cells in 60-mm culture dishes were labeled with [3H]myristic acid (3.0 μCi) for 4–6 h, and 1-BtOH (0.8%) was added 20 min before lipids were collected. Lipids were extracted and characterized by thin layer chromatography as described previously (17). Relative levels of PLD activity were then determined by measuring the intensity of the corresponding phosphatidyl-BtOH band in the autoradiograph with ImageJ software or by scraping the thin layer chromatography plates and scintillation counting of the phosphatidyl-BtOH band.
RESULTS
PLD Activity in Human Cancer Cells Is Dependent on Amino Acids and Glucose
We reported previously that the PLD activity is elevated in several human cancer cell lines, especially those harboring Ras mutations (35–37). The PA generated by PLD is required for the activation of mTORC1 (32). mTORC1 is a sensor of nutritional sufficiency and is active in the presence of amino acids and glucose (1–4). We therefore examined whether the elevated PLD activity observed in human cancer cell lines was dependent on the presence of essential amino acids and glucose. MDA-MB-231 breast, T24 bladder, and Calu-1 lung cancer cells all display elevated PLD activity, especially when deprived of serum (35, 36). All three of these cell lines harbor Ras mutations, which contribute to the elevated PLD activity (36, 37). The PLD activity in the MDA-MB-231, T24, and Calu-1 cells was evaluated in the presence and absence of essential amino acids (Fig. 1A) and glucose (Fig. 1B). As shown, the level of PLD activity in all three cell lines was substantially reduced when the medium lacked either amino acids or glucose. The nutrient-dependent PLD activity in all three cell lines was partially sensitive to selective inhibitors of both PLD1 (compound 14) and PLD2 (compound 22a), indicating that both PLD1 and PLD2 are likely to be involved. These data indicate that the elevated PLD activity in these cancer cell lines is dependent on both essential amino acids and glucose and that PLD may be critical for the response to nutritional sufficiency.
FIGURE 1.
PLD activity in human cancer cells is dependent on amino acids and glucose. MDA-MB-231, T24, and Calu-1 cells were plated at 80% confluence for 24 h, at which time they were shifted to medium containing 0.5% serum and either complete DMEM or DMEM lacking either essential amino acids (w/o AA) (A) or glucose (w/o Glu) (B) for 4 h along with [3H]myristic acid to label the lipids. 1-BtOH was then added for 20 min, and the transphosphatidylation product phosphatidyl BtOH was determined as described under “Experimental Procedures.” Values were normalized to the levels of PLD in complete medium (DMEM) controls, which were given a value of 100%. C, MDA-MB-231, T24, and Calu-1 cells were plated as in A and B. The cells were shifted to medium lacking serum for 4 h. The PLD1 inhibitor Compound 14 (33, 34) and the PLD2 inhibitor Compound 22A (34) were added at the concentrations indicated for 1 h, at which time the cells were labeled with [3H]myristate, and the relative PLD activity was then determined as in A and B. Error bars, S.D. values for at least two independent experiments.
Amino Acid- and Glucose-induced Increases in mTORC1 Activity Are Dependent on PLD Activity
The ability of amino acids to activate mTORC1 has been widely reported (3). Chen and colleagues (20) recently reported that serum-induced phosphorylation of the mTORC1 site on p70 S6 kinase (p70S6K) (Thr389) was dependent on the presence of amino acids. Chen's group (20) also demonstrated that serum-induced PLD activity was dependent on amino acids. These data are consistent with an amino acid and PLD dependence for serum-induced mTORC1 activation. We therefore examined whether amino acid-stimulated p70S6K phosphorylation in MDA-MB-231, T24, and Calu-1 cells was dependent on PLD activity. Cells were shifted to medium lacking serum overnight, at which time the cells were then placed in medium lacking both serum and essential amino acids. Four hours later, amino acids were added in the presence of either 1-BtOH or t-BtOH, and p70S6K phosphorylation at Thr389 was examined 30 min later. Whereas 1-BtOH suppresses the production of PA by PLD via the transphosphatidylation reaction, t-BtOH cannot participate in this reaction and is used as a negative control (17). 1-BtOH, but not t-BtOH, suppressed the amino acid-induced increase in p70S6K phosphorylation in all three cell lines (Fig. 2A). These data indicate that the induction of mTORC1 by amino acids is dependent on PLD activity.
FIGURE 2.
Amino acid- and glucose-induced increases in mTORC1 activity are dependent on PLD activity. MDA-MB-231, T24, and Calu-1 cells were plated in 6-well plates at 50% confluence and then placed in medium containing 10% serum overnight. The cells were then shifted to medium lacking serum for 24 h. The cells were then shifted to medium lacking either essential amino acids (A) or glucose (B). 4 h later, amino acids or glucose were added back in the presence of either 1-BtOH or t-BtOH, as indicated. Cells were harvested 30 min later, and p70S6K phosphorylation at Thr389 (P-p70S6K) was examined by Western blot. The data shown are representative experiments repeated at least two times. The levels of phospho-p70S6K relative to the level of p70S6K were determined by densitometer and normalized to the level observed in the absence of amino acids (A) or glucose (B) and are provided above each blot. The data shown are for representative experiments repeated at least two times. C, T24 cells were prepared and treated as in A and B. Amino acids or glucose were added as indicated in the presence of the indicated concentration of the PLD inhibitors 14 and 22A. Phospho-p70S6K was examined 30 min later as in A and B. Shown is a representative experiment as well as a graphic representation for two independent experiments with error bars representing S.D. values.
We also examined the PLD dependence for the activation of mTORC1 by glucose. MDA-MB-231, T24, and Calu-1 cells were placed in medium lacking serum overnight and then shifted to medium lacking both serum and glucose. Four hours later, glucose was added along with either 1-BtOH or t-BtOH, and the phosphorylation of p70S6K was evaluated 30 min later. As shown in Fig. 2B, the induction of p70S6K phosphorylation was suppressed by 1-BtOH but not by t-BtOH. We also examined the effect of the PLD inhibitors on the amino acid- and glucose-induced increases in p70S6K phosphorylation. As shown in Fig. 2C, the combination of Compounds 14 and 22a suppressed the induction of p70S6K phosphorylation by both amino acids and glucose in the T24 cells. Neither of the inhibitors alone had a significantly stronger impact of p70S6K phosphorylation (data not shown), making it likely that both PLD1 and PLD2 are involved. These data further implicate PLD activity for the induction of mTORC1 with either glucose or amino acids.
Elevated PLD Activity and Nutrient-dependent mTORC1 Activity in Human Cancer Cells Is Dependent on Rheb
Chen and colleagues (20, 38) recently reported that serum-induced PLD activity was at least partially dependent on Rheb and that Rheb could be co-immunoprecipitated with PLD1. We therefore examined whether the amino acid-dependent PLD activity in human cancer cells was dependent on Rheb. As shown in Fig. 3A, suppression of Rheb expression with siRNA suppressed the amino acid-dependent PLD activity in MDA-MB-231, T24, and Calu-1 cells. Consistent with previous reports (2), knockdown of Rheb also suppressed the amino acid-induced phosphorylation of p70S6K phosphorylation at the mTORC1 Thr389 site (Fig. 3B). We also examined the impact of suppressing Rheb expression on the stimulation of mTORC1 with glucose in the T24 cells. As shown in Fig. 3C, the glucose-induced increase in p70S6K phosphorylation was also dependent on Rheb. These data demonstrate that nutrient-dependent PLD activity is dependent on Rheb and that the nutrient induction of mTORC1 is also dependent on Rheb.
FIGURE 3.
Elevated PLD activity and nutrient dependent mTORC1 activity in human cancer cells is dependent on Rheb. A, MDA-MB-231, T24, and Calu-1 cells were plated at 30% confluence overnight. The cells were transfected with Rheb siRNA or a scrambled (Scram) control siRNA. 24 h later, the cells were treated with fresh medium containing 10% serum for an additional 24 h, at which time the cells were shifted to medium containing 0.5% serum for an additional 24 h. The cells were then harvested, and the PLD activity was determined as in Fig. 1. B, cells were first transfected with Rheb or scrambled siRNA as in A. After overnight incubation in medium containing 0.5% serum, the cells were placed in medium containing 0% serum for 4 h lacking essential amino acids or glucose. Where indicated, amino acids or glucose were added back for 30 min, and p70S6K phosphorylation was determined by Western blot using an antibody specific for Thr389. The levels of p70S6K protein, Rheb, and actin were also determined by Western blot. C, T24 cells were treated as in B with Rheb or scrambled siRNA and then put in medium lacking glucose for 4 h. Glucose was then added where indicated, and the levels of phosphorylated p70S6K, p70S6K, Rheb, and actin were determined 30 min later by Western blot analysis. The data shown are representative experiments repeated at least two times. The levels of phospho-p70S6K (P-p70S6K) relative to p70S6K were determined as in Fig. 2.
Amino Acids Do Not Impact on TSC
The amino acid induction of mTORC1 is dependent on Rheb and therefore also dependent on the suppression of TSC1/2, which suppresses Rheb by stimulating the hydrolysis of GTP to GDP (4). We therefore investigated the impact of amino acids on the phosphorylation state of TSC2, which is both activated and suppressed by phosphorylation at different sites (39). Akt phosphorylates TSC2 at Thr1462, which leads to the suppression of the GTPase activity of Rheb (39). As shown in Fig. 4A, amino acids had no effect on the phosphorylation state of TSC2 at Thr1462 in either the MDA-MB-231 or T24 cells. Suppression of PA generation by PLD with 1-BtOH also had no effect on the phosphorylation of TSC2 at this site (Fig. 4A). In contrast, insulin was able to increase phosphorylation at this site (Fig. 4B). TSC2 is phosphorylated by Akt, which is activated by PI3K (39). Importantly, suppression of PI3K with wortmannin was able to suppress TSC2 phosphorylation at Thr1462, and this led to reduced phosphorylation of p70S6K at Thr389. Collectively, the data in Figs. 3 and 4 indicate that although signaling through TSC and Rheb is required for the amino acid induction of PLD and mTORC1, this signaling pathway is not impacted by amino acids. These findings are consistent with previous reports indicating that nutrient signaling to mTOR does not up-regulate the TSC-Rheb pathway (4).
FIGURE 4.
Amino acids do not impact on TSC. A, MDA-MB-231 and T24 cells were plated as in Fig. 1 and then shifted to medium containing 0% serum overnight. The cells were then shifted to medium lacking essential amino acids for 4 h. Where indicated, amino acids were added back in the presence of either 1-BtOH or t-BtOH for 30 min, and TSC2 phosphorylation was then determined by Western blot using an antibody specific for TSC2 phosphorylated at Thr1462. The levels of phosphorylated TSC2 relative to TSC2 are provided. B, MDA-MB-231 and T24 cells were prepared and treated as in A. Where indicated, amino acids were added back in the presence of either insulin or wortmannin (Wort) for 30 min, and TSC2 phosphorylation was then determined as in A. The levels of p70S6K phosphorylation were also determined as in Figs. 2 and 3. The levels of phosphorylated TSC2 relative to the actin loading controls are shown. The data shown are for representative experiments repeated at least two times.
Amino Acid and Glucose-dependent PLD Activity Is Dependent on RalA
The lack of an impact of amino acids on TSC1/2 suggest that the amino acid-stimulated increase may be acting through the regulation of PLD and does not involve changes in the activity of Rheb. The amino acid-stimulated increase in mTORC1 activity was reported to be dependent on RalA (12). The RalA dependence for the amino acid-dependent activation of mTORC1 is particularly intriguing in that RalA is constitutively associated with PLD1 (13, 14) and is required for the recruitment of activating ARF family GTPases to PLD1 (18). RalA was knocked down with siRNA, and the impact on amino acid-dependent PLD activity was evaluated in the MDA-MB-231 and T24 cells. As shown in Fig. 5A, the amino acid-dependent PLD activity in both cell lines was dependent on RalA. We next examined the effect of RalA knockdown on the induction of p70S6K phosphorylation by amino acids. As shown in Fig. 5B, RalA knockdown suppressed the amino acid induction of p70S6K phosphorylation at the mTORC1 site at Thr389 in both the MDA-MB-231 and T24 cells. The induction of p70S6K phosphorylation by glucose was similarly suppressed by RalA knockdown in the T24 cells (Fig. 5C). In contrast, the serum induction of p70S6K phosphorylation was not impacted by RalA knockdown in these cells (Fig. 5C). These data are consistent with RalA being a key target of nutrients for the activation of mTORC1 and further implicate PLD1, which interacts directly with RalA as a conduit to mTORC1 activation.
FIGURE 5.
Amino acid- and glucose-dependent PLD activity is dependent on RalA. A, MDA-MB-231 and T24 cells were plated at 30% confluence overnight. The cells were transfected with RalA siRNA or scrambled (Scram) control siRNA. 24 h later, the cells were treated with fresh medium containing 10% serum for an additional 24 h, at which time the cells were shifted to medium containing 0.5% serum for an additional 24 h. The cells were then harvested, and the PLD activity was determined as in Fig. 1. B, cells were transfected with RalA or scrambled siRNA as in A. The cells were then placed in medium containing 0% serum for overnight and then switched to medium lacking essential amino acids for 4 h. Where indicated, amino acids were added back for 30 min, and p70S6K phosphorylation was determined by Western blot using an antibody specific for Thr389. The levels of p70S6K protein and RalA were also determined by Western blot. C, T24 cells were treated as in B with RalA or scrambled siRNA and then put in medium lacking serum (all lanes) and either amino acids or glucose as indicated for 4 h. Serum, amino acids, and glucose were then added where indicated, and the levels of p70S6K phosphorylation, RalA, and actin were determined 30 min later by Western blot analysis. The levels of phospho-p70S6K (P-p70S6K) relative to p70S6K were determined as in Fig. 2. Shown is a representative experiment. Also shown is a graphic representation of two independent experiments with error bars representing S.D. values.
Amino Acid and Glucose-dependent PLD Activity Is Dependent on ARF6
We previously reported that RalA promotes the activation of PLD1 by recruitment of ARF family GTPases into a RalA-PLD1 complex (14, 18). We also demonstrated that H-Ras-induced PLD activity was dependent on ARF6 (40). ARF6 has also been implicated in the glucose stimulation of insulin secretion (19), indicating that ARF6 is activated in response to nutrients. Thus, the involvement of RalA, in the amino acid- and glucose-dependent PLD activity shown in Fig. 5 suggests the possible involvement of ARF GTPases, which are direct activators of PLD1 (41). As reported previously for the MDA-MB-231 cells (37), knockdown of either ARF1 or ARF6 with siRNA suppressed the nutrient-dependent PLD activity in the T24 cells (Fig. 6A). As shown in Fig. 6B, ARF6 knockdown suppressed the induction of p70S6K phosphorylation by both amino acids and by glucose in the T24 cells. As with RalA, the serum induction of p70S6K phosphorylation was not impacted by ARF6 knockdown. In contrast with ARF6, knockdown of ARF1 did not affect the stimulation of p70S6K phosphorylation by amino acids, glucose, or serum (Fig. 6C). These data are consistent with ARF6 being a key target of nutrients for the activation of mTORC1 and further implicate PLD1, which interacts directly with RalA as a conduit to mTORC1 activation.
FIGURE 6.
Amino acid- and glucose-dependent PLD activity is dependent on ARF6. A, T24 cells were treated as in Fig. 5C with either ARF6 or ARF1 siRNAs or scrambled (Scram) siRNA as indicated and then put in medium lacking serum overnight, at which time the PLD activity was evaluated as described under “Experimental Procedures.” Values were normalized to the control scrambled siRNAs, which were given a value of 100%. B and C, T24 cells were treated as in A with either ARF6 (B) or ARF1 (C) siRNAs or scrambled siRNA controls and then put in medium lacking serum (all lanes) and either amino acids or glucose as indicated for 4 h. Serum, amino acids, and glucose were then added where indicated, and the levels of p70S6K phosphorylation, ARF6, ARF1, and actin were determined 30 min later by Western blot analysis. The levels of phospho-p70S6K (P-p70S6K) relative to p70S6K were determined as in Fig. 2. Shown are representative experiments. For B, a graphic representation of two independent experiments with error bars representing S.D. values is also provided.
hVps34 Is Required for Amino Acid-dependent PLD Activity
hVps34 has been implicated in amino acid-stimulated activation of mTORC1 (22–25). hVps34 is intriguing in that it is a type III PI3K kinase that generates PI-3-P, which interacts with PX domains, and significantly, both PLD1 and PLD2 have a PX domain that is critical for activity (27, 28). We therefore examined whether hVps34 was required for the amino acid-dependent PLD activity in the T24 cells. As shown in Fig. 7A, siRNA knockdown of hVps34 suppressed the amino acid-dependent PLD activity. We also examined the effect of suppressing hVps15 (formerly known as P150) on PLD activity in the T24 cells. hVPS15 regulates the activity of hVps34 and has also been implicated in nutrient sensing (42). As shown in Fig. 7A, hVPS15 also suppressed the PLD activity in these cells. These data are consistent with our previous finding that the PI3K inhibitor LY294002 strongly inhibited PLD activity in the T24 and Calu-1 cells (36). We next examined whether the knockdown of hVps34 suppressed the induction of p70S6K phosphorylation by serum, amino acids, and glucose. We were unable to detect significant effects upon the phosphorylation of p70S6K in the T24 cells (data not shown). However, because the hVps34 has been shown previously to be required for amino acid-induced increases in mTORC1 activity (22–25), we examined the effect of suppressing the hVps15. As shown in Fig. 7B, suppression of hVps15 expression suppressed both the amino acid and glucose induction of p70S6K phosphorylation in T24 cells. It is not clear at this point why the knockdown of hVps15 was more effective than knockdown of hVps34, but the effect of hVps15 and hVps34 siRNAs on the amino acid- and glucose-dependent PLD activity suggests that the signals generated by hVps34 that lead to mTORC1 go through PLD.
FIGURE 7.
hVps34 is required for amino acid-dependent PLD activity. A, T24 cells were plated at 30% confluence overnight. The cells were transfected with hVps34, hVps15, or scrambled control siRNA as indicated. 24 h later, the cells were treated with fresh medium containing 10% serum for an additional 24 h, at which time the cells were shifted to medium containing 0.5% serum for an additional 24 h. The cells were then harvested, and the relative PLD activity was determined as described under “Experimental Procedures.” Values were normalized to the control scrambled siRNAs, which were given a value of 100%. B, T24 cells were treated with either hVps15 or scrambled siRNA and then put in medium lacking serum (all lanes) and either amino acids or glucose as indicated for 4 h. Serum, amino acids, and glucose were then added where indicated, and the levels of p70S6K phosphorylation, hVps15, and actin were determined 30 min later by Western blot analysis. The levels of phospho-p70S6K (P-p70S6K) relative to p70S6K were determined as in Fig. 2. Shown is a representative experiment. Also shown is a graphic representation of three independent experiments with error bars representing S.D. values.
DISCUSSION
In this report, we have provided evidence that nutrient stimulation of mTORC1 is dependent on PLD activity. Whereas growth factor stimulation of mTORC1 is largely regulated through the PI3K/Akt/TSC/Rheb pathway, this signaling pathway is not impacted by nutrients (4). Thus, the finding that nutrients are feeding into PLD reveals a novel mechanism for activating mTORC1. Although nutrients do not impact on Rheb GTP loading (5–7), Rheb is clearly required for the nutrient-dependent increase in mTORC1. Significantly, Rheb was required for the nutrient-dependent PLD activity, which is consistent with a report from the Chen group (20) that has shown that Rheb interacts with and contributes to the activation of PLD1. The activation of nutrient-dependent mTORC1 activity was also dependent on the GTPases RalA and ARF6. Both of these GTPases have been implicated in both response to nutrients (12, 19, 43) and stimulation of PLD activity (13, 14, 18, 40). RalA is constitutively associated with PLD1 but does not activate PLD1 by itself. RalA contributes to the activation of PLD1 by recruiting ARF6, which does activate PLD1 activity, into a RalA-ARF6-PLD1 complex (18). Although it is still not clear from data provided here or elsewhere how the presence of nutrients activates RalA and ARF6, the data provided here indicate that a key target of RalA and ARF6 for the stimulation of mTORC1 is PLD1.
The involvement of RalA and ARF6 in the nutrient-dependent increases in PLD and mTORC1 activity implicates PLD1, which is constitutively associated with RalA (14). However, PLD2 has also been implicated in the regulation of mTORC1. Exogenously expressed PLD2 was shown to increase p70S6K phosphorylation in MCF7 cells (44). It was also reported that PLD2 forms a functional complex with mTOR and Raptor, and this interaction was essential for mitogen stimulation of mTORC1 (45). More recently, dominant negative mutants of both PLD1 and PLD2 were able to suppress the activation of mTORC1 (17). Data provided here reveal that the nutrient-dependent PLD activity in the cells used in this study were sensitive to PLD inhibitors specific for both PLD1 and PLD2. Thus, it would appear that both PLD1 and PLD2 are involved in the nutrient-dependent activation of mTORC1. In this regard, it is of interest that hVps34 is also probably required for nutrient-dependent PLD activity and mTORC1 activation. hVps34 stimulates the production of PI-3-P, which serves to recruit proteins with PX domains (26), and both PLD1 and PLD2 contain PX domains (27, 28). Thus, the apparent involvement of PLD2 as well as PLD1 may involve the activation of hVps34.
Interestingly, Neufeld and colleagues (46) reported that in Drosophila, although Vps34 promotes autophagy and endocytosis, it does not stimulate TOR signaling. However, as reviewed by Sun and Chen (38), Drosophila TOR is not likely to be regulated by PA and PLD. This is because Drosophila TOR lacks the Arg at 2109 that is critical for PA binding to mTOR (15, 47). Moreover, an RNAi screen that included PLD did not lead to a phenotype indicative of any involvement in the activation of TOR (48). Also of interest in this regard is a study with Drosophila that implicated ARF GTPases in the regulation of nutrient input into Drosophila TOR. In this study, ARF1 rather than ARF6 was implicated (43), further distinguishing the regulation of TOR in Drosophila and in mammals, where PLD activity and PA have been implicated.
Sabatini and colleagues (9–11) recently reported that mTORC1 is targeted to lysosomal membranes by Rag GTPases in response to amino acids. They went on to show that constitutive targeting of mTORC1 to the lysosomal surface was sufficient to render the mTORC1 pathway amino acid-insensitive and independent of Rag (10), leading them to propose that Rag-mediated translocation of mTORC1 to lysosomal membranes is the key event in amino acid signaling to mTORC1. It was hypothesized that mTORC1 was activated by simply bringing mTORC1 to where GTP-bound Rheb was localized, accounting for the activation of mTORC1 in response to amino acids. Our data are consistent with this model in that there is agreement that Rheb is critical for the activation of mTORC1 in response to amino acids. However, our study also takes into account previous studies linking the nutrient response of mTORC1 to RalA (12), ARF6 (19), and hVps34 (22–25). A common denominator for all three of these factors is PLD and a direct link to mTORC1 through PA. Moreover, we have also demonstrated here that PLD also mediates the response of mTORC1 to glucose. It has not yet been demonstrated whether glucose, like amino acids would stimulate the Rag-mediated translocation to lysosomal membranes. It is possible that glucose might target mTORC1 to a separate location where glucose metabolism is more relevant. The findings presented here are consistent with a model whereby growth factors elevate mTORC1 activity through changes in Rheb GTP loading mediated by PI3K signaling, and nutrients stimulate mTORC1 activity by stimulating PLD activity and the generation of PA, which stabilizes the mTOR-Raptor association (17). A model for the activation of mTORC1 by growth factors and nutrients is shown in Fig. 8.
FIGURE 8.
Model for nutrient-induced mTORC1 activity. A working model is presented where there are two major inputs into mTORC1, one mediated by growth factors and energy and another mediated by nutrient sufficiency. The growth factors keep Rheb in a GTP-bound state through suppression of the tuberous sclerosis complex, TSC. Although GTP-bound Rheb is required for nutrient stimulation of mTORC1, Rheb itself is not affected by nutrients. Amino acids stimulate the recruitment of mTORC1 via Rag GTPases to lysosomal membranes where nutrients stimulate the activity of mTORC1 via the activation of PLD1 and possibly PLD2 by the activation of RalA, ARF6, and hVps34. Interestingly, Rheb is required for PLD activity, revealing cross-talk between the two inputs into mTORC1 activation. Elevated PLD activity generates the PA necessary for the association between mTOR and Raptor, which is essential for mTORC1 activity.
All of the data presented here were obtained in human cancer cells, where elevated PLD activity provides a survival signal that suppresses default apoptotic signals (32). Although this study was made more feasible because of the elevated PLD activity in these cells, there are also implications that have relevance for treatment strategies in cancer. Suppression of PLD activity in the MDA-MB-231, T24, and Calu-1 cells used in this study results in apoptosis in the absence of serum (36, 44, 49). Similarly, rapamycin causes apoptosis when these cells are deprived of serum (49).3 Therefore, the finding reported here that the PLD activity in these cells is dependent on nutrient input suggests additional strategies for reversing the survival signals in cancer cells by targeting the nutrient sources and signals generated by nutrients. Consistent with this hypothesis, Blenis and colleagues (50) have reported recently that TSC2 null cells, which have hyperactive mTORC1 signals, are uniquely sensitive to deprivation of the nutrients glucose and glutamine.
Acknowledgment
We thank Dr. H. Alex Brown for the PLD inhibitors used in this study and for several helpful discussions.
This work was supported, in whole or in part, by National Institutes of Health, NCI, Grant CA148677. This work was also supported by Research Centers in Minority Institutions Award RR-03039 from the National Center for Research Resources of the National Institutes of Health, which supports infrastructure and instrumentation in the Biological Sciences Department at Hunter College.
L. Xu, D. Salloum, P. S. Medlin, M. Saqcena, P. Yellen, B. Perrella, and D. A. Foster, unpublished observations.
- mTOR
- mammalian target of rapamycin
- mTORC1 and mTORC2
- mTOR complex 1 and 2, respectively
- ARF
- ADP-ribosylation factor
- BtOH
- butanol
- PA
- phosphatidic acid
- PI
- phosphatidylinositol
- PI-3-P
- PI-3-phosphate
- PLD
- phospholipase D
- TSC
- tuberous sclerosis complex.
REFERENCES
- 1. Fingar D. C., Blenis J. (2004) Oncogene 23, 3151–3171 [DOI] [PubMed] [Google Scholar]
- 2. Avruch J., Hara K., Lin Y., Liu M., Long X., Ortiz-Vega S., Yonezawa K. (2006) Oncogene 25, 6361–6372 [DOI] [PubMed] [Google Scholar]
- 3. Avruch J., Long X., Ortiz-Vega S., Rapley J., Papageorgiou A., Dai N. (2009) Am. J. Physiol. Endocrinol. Metab. 296, E592–E602 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Wang X., Proud C. G. (2009) Trends. Cell Biol. 19, 260–267 [DOI] [PubMed] [Google Scholar]
- 5. Smith E. M., Finn S. G., Tee A. R., Browne G. J., Proud C. G. (2005) J. Biol. Chem. 280, 18717–18727 [DOI] [PubMed] [Google Scholar]
- 6. Long X., Ortiz-Vega S., Lin Y., Avruch J. (2005) J. Biol. Chem. 280, 23433–23436 [DOI] [PubMed] [Google Scholar]
- 7. Roccio M., Bos J. L., Zwartkruis F. J. (2006) Oncogene 25, 657–664 [DOI] [PubMed] [Google Scholar]
- 8. Kim E., Goraksha-Hicks P., Li L., Newfeld T. P., Guan K. L. (2008) Nat. Cell Biol. 10, 935–945 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Sancak Y., Peterson T. R., Shaul Y. D., Lindquist R. A., Thoreen C. C., Bar-Peled L., Sabatini D. M. (2008) Science 320, 1496–1501 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Sancak Y., Bar-Peled L., Zoncu R., Markhard A. L., Nada S., Sabatini D. M. (2010) Cell 141, 290–303 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Sancak Y., Sabatini D. M. (2009) Biochem. Soc. Trans. 39, 289–290 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Maehama T., Tanaka M., Nishina H., Murakami M., Kanaho Y., Hanada K. (2008) J. Biol. Chem. 283, 35053–35059 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Jiang H., Luo J. Q., Urano T., Frankel P., Lu Z., Foster D. A., Feig L. A. (1995) Nature 378, 409–412 [DOI] [PubMed] [Google Scholar]
- 14. Luo J. Q., Liu X., Hammond S. M., Colley W. C., Feig L. A., Frohman M. A., Morris A. J., Foster D. A. (1997) Biochem. Biophys. Res. Commun. 235, 854–859 [DOI] [PubMed] [Google Scholar]
- 15. Fang Y., Vilella-Bach M., Bachmann R., Flanigan A., Chen J. (2001) Science 294, 1942–1945 [DOI] [PubMed] [Google Scholar]
- 16. Chen Y., Zheng Y., Foster D. A. (2003) Oncogene 22, 3937–3942 [DOI] [PubMed] [Google Scholar]
- 17. Toschi A., Lee E., Xu L., Garcia A., Gadir N., Foster D. A. (2009) Mol. Cell. Biol. 29, 1411–1420 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Luo J. Q., Liu X., Frankel P., Rotunda T., Ramos M., Flom J., Jiang H., Feig L. A., Morris A. J., Kahn R. A., Foster D. A. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 3632–3637 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Ma W. N., Park S. Y., Han J. S. (2010) Exp. Mol. Med. 42, 456–464 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Sun Y., Fang Y., Yoon M. S., Zhang C., Roccio M., Zwartkruis F. J., Armstrong M., Brown H. A., Chen J. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 8286–8291 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Sato T., Nakashima A., Guo L., Coffman K., Tamanoi F. (2010) Oncogene 29, 2746–2752 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Byfield M. P., Murray J. T., Backer J. M. (2005) J. Biol. Chem. 280, 33076–33082 [DOI] [PubMed] [Google Scholar]
- 23. Nobukuni T., Joaquin M., Roccio M., Dann S. G., Kim S. Y., Gulati P., Byfield M. P., Backer J. M., Natt F., Bos J. L., Zwartkruis F. J., Thomas G. (2005) Proc. Natl. Acad. Sci. U.S.A. 102, 14238–14243 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Nobukuni T., Kozma S. C., Thomas G. (2007) Curr. Opin. Cell Biol. 19, 135–141 [DOI] [PubMed] [Google Scholar]
- 25. Gulati P., Gaspers L. D., Dann S. G., Joaquin M., Nobukuni T., Natt F., Kozma S. C., Thomas A. P., Thomas G. (2008) Cell Metab. 7, 456–465 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Backer J. M. (2008) Biochem. J. 410, 1–17 [DOI] [PubMed] [Google Scholar]
- 27. Frohman M. A., Morris A. J. (1999) Chem. Phys. Lipids. 98, 127–140 [DOI] [PubMed] [Google Scholar]
- 28. Morris A. J. (2007) Biochem. Soc. Symp. 74, 247–257 [DOI] [PubMed] [Google Scholar]
- 29. Guertin D. A., Sabatini D. M. (2007) Cancer Cell. 12, 9–22 [DOI] [PubMed] [Google Scholar]
- 30. Foster D. A. (2004) Expert. Rev. Anticancer Ther. 4, 691–701 [DOI] [PubMed] [Google Scholar]
- 31. Hay N. (2005) Cancer Cell 8, 179–183 [DOI] [PubMed] [Google Scholar]
- 32. Foster D. A. (2009) Biochim. Biophys. Acta 1791, 949–955 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Lewis J. A., Scott S. A., Lavieri R., Buck J. R., Selvy P. E., Stoops S. L., Armstrong M. D., Brown H. A., Lindsley C. W. (2009) Bioorg. Med. Chem. Lett. 19, 1916–1920 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Lavieri R. R., Scott S. A., Selvy P. E., Kim K., Jadhav S., Morrison R. D., Daniels J. S., Brown H. A., Lindsley C. W. (2010) J. Med. Chem. 53, 6706–6719 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Zheng Y., Rodrik V., Toschi A., Shi M., Hui L., Shen Y., Foster D. A. (2006) J. Biol. Chem. 281, 15862–15868 [DOI] [PubMed] [Google Scholar]
- 36. Shi M., Zheng Y., Garcia A., Xu L., Foster D. A. (2007) Cancer Lett. 258, 268–275 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Garcia A., Zheng Y., Zhao C., Toschi A., Fan J., Shraibman N., Brown H. A., Bar-Sagi D., Foster D. A., Arbiser J. L. (2008) Clin. Cancer Res. 14, 4267–4274 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Sun Y., Chen J. (2008) Cell Cycle 7, 3118–3123 [DOI] [PubMed] [Google Scholar]
- 39. Kwiatkowski D. J., Manning B. D. (2005) Hum. Mol. Genet. 14, R251–258 [DOI] [PubMed] [Google Scholar]
- 40. Xu L., Frankel P., Jackson D., Rotunda T., Boshans R. L., D'Souza-Schorey C., Foster D. A. (2003) Mol. Cell Biol. 23, 645–654 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Exton J. H. (2002) Rev. Physiol. Biochem. Pharmacol. 144, 1–94 [DOI] [PubMed] [Google Scholar]
- 42. Yan Y., Flinn R. J., Wu H., Schnur R. S., Backer J. M. (2009) Biochem. J. 417, 747–755 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Li L., Kim E., Yuan H., Inoki K., Goraksha-Hicks P., Schiesher R. L., Neufeld T. P., Guan K. L. (2010) J. Biol. Chem. 285, 19705–19709 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Chen Y., Rodrik V., Foster D. A. (2005) Oncogene 24, 672–679 [DOI] [PubMed] [Google Scholar]
- 45. Ha S. H., Kim D. H., Kim I. S., Kim J. H., Lee M. N., Lee H. J., Kim J. H., Jang S. K., Suh P. G., Ryu S. H. (2006) Cell. Signal. 18, 2283–2291 [DOI] [PubMed] [Google Scholar]
- 46. Juhász G., Hill J. H., Yan Y., Sass M., Baehrecke E. H., Backer J. M., Neufeld T. P. (2008) J. Cell Biol. 181, 655–666 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Veverka V., Crabbe T., Bird I., Lennie G., Muskett F. W., Taylor R. J., Carr M. D. (2008) Oncogene 27, 585–595 [DOI] [PubMed] [Google Scholar]
- 48. Björklund M., Taipale M., Varjosalo M., Saharinen J., Lahdenperä J., Taipale J. (2006) Nature 439, 1009–1013 [DOI] [PubMed] [Google Scholar]
- 49. Gadir N., Jackson D. N., Lee E., Foster D. A. (2008) Oncogene 27, 1055–1062 [DOI] [PubMed] [Google Scholar]
- 50. Choo A. Y., Kim S. G., Vander Heiden M. G., Mahoney S. J., Vu H., Yoon S. O., Cantley L. C., Blenis J. (2010) Mol. Cell. 38, 487–499 [DOI] [PMC free article] [PubMed] [Google Scholar]